This is a working overview of pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
== History == Pyridoxine was discovered in 1934, isolated in 1938, and first made in 1939. It is on the World Health Organization's List of Essential Medicines. Pyridoxine is available both as a generic medication and over the counter product. Foods, such as breakfast cereal have pyridoxine added in some countries.
=== Recreational use === Zopiclone has the potential for non-medical use, dosage escalation, and drug dependence. It is taken orally and sometimes intravenously when used non-medically, and often combined with alcohol to achieve euphoria. Patients abusing the drug are also at risk of dependence. Withdrawal symptoms can be seen after long-term use of normal doses even after a gradual reduction regimen. The Compendium of Pharmaceuticals and Specialties recommends zopiclone prescriptions not exceed 7 to 10 days, owing to concerns of addiction, tolerance, and physical dependence. Two types of drug misuse can occur: either recreational misuse, wherein the drug is taken to achieve a high, or when the drug is continued long-term against medical advice. Zopiclone is as addictive as or may be more addictive than benzodiazepines. Those with a history of substance misuse or mental health disorders may be at an increased risk of high-dose zopiclone misuse. High-dose misuse of zopiclone and increasing popularity amongst people who use substances who have been prescribed with zopiclone was shown in the 1990s. The symptoms of zopiclone addiction can include depression, dysphoria, hopelessness, slow thoughts, social isolation, worrying, sexual anhedonia, and nervousness. Zopiclone and other sedative hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Other sedating drugs, including benzodiazepines and zolpidem, are also found in high numbers of suspected drugged drivers.
There is evidence to suggest that excitatory amino acids like quisqualic acid play a significant role in the induction of cell death following stroke, hypoxia-ischemia, and traumatic brain injury . Studies involving the binding of quisqualic acid have indicated that the amino acid does not show selectivity for a singular specific receptor subtype, which was initially identified as the quisqualate receptor. Instead, it demonstrates high affinity for other types of excitatory amino acid receptors, including kainate, AMPA, and metabotropic receptors, as well as some transport sites, such as the chloride-dependent L-AP4-sensitive sites. In addition, it also exhibits affinity for certain enzymes responsible for cleaving dipeptides, including the enzyme responsible for cleaving N-acetyl-aspartylglutamate (NAALADase) . Regarding bioavailability, no database information is present, as there is limited research on its pharmacokinetics. However, even though the bioavailability is not well established, studies in rats suggest that age may play a role in the presence of administered quisqualic acid effects. An experiment which was done on rats within two age groups (20-days-old and 60-days-old) showed that, when given quisqualic acid microinjections, 60-day-old rats had more seizures compared to the younger rats. Additionally, the rats were given the same amount of quisqualic acid, however the immature animals received a higher dosage per body weight, implying that the harm inflicted by the excitatory amino acid may have been comparatively lower in the younger animals.
During the late-1920s, the Rockefeller Foundation created the Medical Sciences Division, which emerged from the former Division of Medical Education. The division was led by Richard M. Pearce until his death in 1930, to which Alan Gregg succeeded him until 1945. During this period, the Division of Medical Sciences made contributions to research across several fields of psychiatry. In 1935 the foundation granted $100000 to the Institute for Psychoanalysis in Chicago. This grant was renewed in 1938, with payments extending into the early-1940s. This division funded women's contraception and the human reproductive system in general, but also was involved in funding controversial eugenics research. Other funding went into endocrinology departments in American universities, human heredity, mammalian biology, human physiology and anatomy, psychology, and the studies of human sexual behavior by Alfred Kinsey. In the interwar years, the foundation funded public health, nursing, and social work in Eastern and Central Europe. In 1950, the foundation expanded their international program of virus research, establishing field laboratories in Poona, India, Trinidad, Belém, Brazil, Johannesburg, South Africa, Cairo, Egypt, Ibadan, Nigeria, and Cali, Colombia, among others. The foundation funded research into the identification of human viruses, techniques for virus identification, and arthropod-borne viruses. Bristol-Myers Squibb, Johns Hopkins University and the Rockefeller Foundation are currently the subject of a $1 billion lawsuit from Guatemala for "roles in a 1940s U.S.
micronucleus The smaller of the two types of nuclei that occur in pairs in the cells of some ciliated protozoa. Whereas the larger macronucleus is polyploid, the micronucleus is diploid and generally transcriptionally inactive except for the purpose of sexual reproduction, where it has important functions during conjugation.
Sources: en.wikipedia.org
The end of the vaginal canal is blocked off by an endodermal membrane, which separates the opening from the vestibule. In the fifth month, the membrane degenerates but leaves a remnant called the hymen.
== Habitat and distribution == A. campestris is found in fields and grassy areas after rain from late summer onwards worldwide. It is often found on lawns in suburban areas, appearing in small groups, in fairy rings, or solitary. Owing to the demise of horse-drawn vehicles and the subsequent decrease in the number of horses on pasture, the old "white outs" of years gone by are becoming rare events. This species is rarely found in woodland. The mushroom has been reported from Europe, Asia, north Africa, Australia, New Zealand, and North America, including Mexico.
== Etymology and pronunciation == The word synovium is related to the word synovia in its sense meaning "synovial fluid". The latter was coined by Paracelsus. More information is given at Synovial fluid § Etymology and pronunciation.
==== Solution and precipitation ==== The diagram above illustrates the point that a precipitate that is not one of the main species in the solution equilibrium may be formed. At pH just below 5.5 the main species present in a 5 μM solution of Al3+ are aluminium hydroxides Al(OH)2+, AlOH+2 and Al13(OH)7+32, but on raising the pH Al(OH)3 precipitates from the solution. This occurs because Al(OH)3 has a very large lattice energy. As the pH rises more and more Al(OH)3 comes out of solution. This is an example of Le Châtelier's principle in action: Increasing the concentration of the hydroxide ion causes more aluminium hydroxide to precipitate, which removes hydroxide from the solution. When the hydroxide concentration becomes sufficiently high the soluble aluminate, Al(OH)−4, is formed. Another common instance where precipitation occurs is when a metal cation interacts with an anionic ligand to form an electrically neutral complex. If the complex is hydrophobic, it will precipitate out of water. This occurs with the nickel ion Ni2+ and dimethylglyoxime, (dmgH2): in this case the lattice energy of the solid is not particularly large, but it greatly exceeds the energy of solvation of the molecule Ni(dmgH)2.
16 July to 25 September Operation Georgia Tar was a 4th Marine Regiment and 3rd Battalion, 9th Marines clear and search operation northeast of Khe Sanh. the operation resulted in 40 PAVN and one Marine killed.
Sources: en.wikipedia.org
=== Mechanism === The use of NPWT to enhance wound healing is thought to be by removing excess extracellular fluid and decreasing tissue edema, which leads to increased blood flow and stabilization of the wound environment. A reduction in systemic (e.g. interleukins, monocytes) and local mediators of inflammation has been demonstrated in experimental models, while decreased matrix metalloproteinase activity and bacterial burden have been documented clinically. In vivo, NPWT has been shown to increase fibroblast proliferation and migration, collagen organization, and to increase the expression of vascular endothelial growth factor and fibroblast growth factor-2, thereby enhancing wound healing.
=== Localized and overall support === Fabric may be used to provide support for the garment by stabilizing weak sections or by creating a backing or lining for the piece. Darning may be utilized on coarsely-woven fabrics with localized areas of damage.
In response to the February 1945 Yalta Conference directives, a Polish Provisional Government of National Unity was formed in June 1945 under Soviet auspices; it was soon recognized by the United States and many other countries. The Soviet domination was apparent from the beginning, as prominent leaders of the Polish Underground State were brought to trial in Moscow (the "Trial of the Sixteen" of June 1945). In the immediate post-war years, the emerging communist rule was challenged by opposition groups, including militarily by the so-called "cursed soldiers", of whom thousands perished in armed confrontations or were pursued by the Ministry of Public Security and executed. Such guerillas often pinned their hopes on expectations of an imminent outbreak of World War III and defeat of the Soviet Union. The Polish right-wing insurgency faded after the amnesty of February 1947. The Polish people's referendum of June 1946 was arranged by the communist Polish Workers' Party to legitimize its dominance in Polish politics and claim widespread support for the party's policies. Although the Yalta agreement called for free elections, the Polish legislative election of January 1947 was controlled by the communists. Some democratic and pro-Western elements, led by Stanisław Mikołajczyk, former prime minister-in-exile, participated in the Provisional Government and the 1947 elections, but were ultimately eliminated through electoral fraud, intimidation and violence.
Osborne's ligament, also Osborne's band, Osborne's fascia, Osborne's arcade, arcuate ligament of Osborne, or the cubital tunnel retinaculum, refers to either the connective tissue which spans the humeral and ulnar heads of the flexor carpi ulnaris (FCU) or another distinct tissue located between the olecranon process of the ulna and the medial epicondyle of the humerus. It is named after Geoffrey Vaughan Osborne, a British orthopedic surgeon, who described the eponymous tissue in 1957.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.